Inmunova is an Argentine biotechnology company, renowned for its commitment to the research and development of innovative medications. Established in 2009, the company builds on the pioneering work of Dr. Fernando Goldbaum’s Laboratory at Fundación Instituto Leloir.
The company’s primary innovation is its proprietary platform, Immuno Multi Carrier (IMC®), which facilitates the engineering of advanced recombinant vaccines and immunomodulators. This cutting-edge technology has already garnered patents in major markets, including the USA, Canada, EU, Japan, China, India, Brazil, Mexico, and Argentina, indicative of its global potential and scalability.
While Inmunova has yet to report its latest investment round, its strategic positioning in the Biopharma and Biotechnology sectors makes it a compelling prospect for investors looking to capitalize on frontier technologies in healthcare innovation.